Cecere Giovanni 4
4 · TransMedics Group, Inc. · Filed Feb 20, 2026
Research Summary
AI-generated summary of this filing
TransMedics (TMDX) CCO Giovanni Cecere Receives Award
What Happened
Giovanni Cecere, Chief Commercial Officer of TransMedics Group, received equity awards on February 18, 2026: 11,082 restricted stock units (RSUs) and a derivative grant covering 16,734 shares (stock option). Both grants are reported at $0.00 per share (no purchase price); the RSUs represent a contingent right to one share each and the derivative is an option subject to vesting.
Key Details
- Transaction date: 2026-02-18; Form 4 filed 2026-02-20 (timely filing).
- Grants: 11,082 RSUs (F1) and a 16,734-share option/derivative (A). Reported price: $0.00.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote F1: Each RSU represents a contingent right to receive one share.
- Footnote F2: The option vests 25% on Feb 18, 2027, then the remainder in equal monthly installments over the following three years, subject to continued service.
- Transaction type: Award/grant (compensation), not an open-market buy or sell.
Context
RSUs convert to actual shares only as they vest; similarly, the option must vest per the schedule before it can be exercised. Awards like these are common executive compensation and do not by themselves indicate buying or selling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-18+11,082→ 19,057 total - Award
Stock Option (Right to Buy)
[F2]2026-02-18+16,734→ 16,734 totalExercise: $135.50Exp: 2036-02-18→ Common Stock (16,734 underlying)
Footnotes (2)
- [F1]Consists of 11,082 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The option vests as to 25% of the shares underlying the option on February 18, 2027 and as to the remaining shares in equal monthly installments over three years thereafter, subject to continued service.